ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - botulinum toxin type a 50 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a - powder for injection - 50 units - active: botulinum toxin type a 50 units equivalent to incobotulinumtoxina (usan), purified botulinum toxin type a excipient: albumin sucrose - xeomin is indicated in adults for the treatment of: · cervical dystonia · blepharospasm · spasticity of the upper limb · upper facial lines -glabellar frown lines -lateral periorbital lines (crow's feet) - horizontal forehead lines

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - conjugated estrogens 0.3mg;  ; conjugated estrogens 0.3mg (includes 3% overage); conjugated estrogens 0.3mg - tablet - 0.3 mg - active: conjugated estrogens 0.3mg   excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opaglos clear 98z19173 opalux green shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.3mg (includes 3% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode white s-8-28905 opalux green shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.3mg excipient: carnauba wax hyprolose hypromellose     lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose   opacode white ns-78-18011 opadry green 15b21511 sucrose

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - conjugated estrogens 0.625mg;  ; conjugated estrogens 0.625mg (includes 3% overage); conjugated estrogens 0.625mg - tablet - 0.625 mg - active: conjugated estrogens 0.625mg   excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opaglos clear 98z19173 shellac stearic acid sucrose titanium dioxide urethane dimethacrylate luting resin active: conjugated estrogens 0.625mg (includes 3% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode opalux maroon as-3910 shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.625mg excipient: carnauba wax hyprolose hypromellose     lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose   opacode white ns-78-18011 opadry maroon 03b16083 sucrose

ארצות הברית - אנגלית - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - estrogens, conjugated 0.625 mg - prempro or premphase therapy should not be used in women with any of the following conditions: prempro and premphase should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. prempro and premphase should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectable amounts of estrogen and progestin have been identified in the breast milk of women receiving these drugs. caution should be exercised when prempro or premphase is administered to a nursing woman. prempro and premphase are not indicated in children. clinical studies have not been conducted in the pediatric population. there have not been sufficient numbers of geriatric women involved in clinical studies utilizing prempro or premphase to determine whether those over 65 years of age differ from younger subjects in their response to prempro or premphase. the women's health initiative studies in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies (14.6)] . in the whi estrogen-alone substudy (daily ce [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies (14.6)] . the women's health initiative memory study in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo [see warnings and precautions (5.3), and clinical studies (14.7)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see warnings and precautions (5.3), and clinical studies (14.7)] . the effects of renal impairment on the pharmacokinetics of prempro or premphase have not been studied. the effects of hepatic impairment on the pharmacokinetics of prempro or premphase have not been studied.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

hims, inc - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65) -

פיליפינים - אנגלית - FDA (Food And Drug Administration)

animal healtg marketing & services, inc.; distributor: animal healtg marketing & services, inc. - cichorium intybus (kasani seed) , terminalia arjuna (arjuna stem bark) , achillea millifolium (biranjasipha aerial part) , capparis spinosa (himsra root) , cassia occidentalis (kasamarda seed) , tamarix galliea (jhavuka whole plant) , solanum nigrum (kakamachi whole plant) (vet.) - oral drops - 17mg + 8mg + 4mg + 17mg + 4mg + 4mg + 8mg

ארצות הברית - אנגלית - NLM (National Library of Medicine)

allergan, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 0.5 mg -    limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered. femhrt is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe or a history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to femhrt - known liver impairment or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy  femhrt should not be used during pregnancy [see  contraindications (4) ]. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestin

ארצות הברית - אנגלית - NLM (National Library of Medicine)

physicians total care, inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - estrogens, conjugated 0.625 mg - prempro or premphase therapy should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active deep vein thrombosis, pulmonary embolism or a history of these conditions - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions - known liver dysfunction or disease - known thrombophilic disorders (e.g., protein c, protein s, or antithrombin deficiency) - known or suspected pregnancy prempro and premphase should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. prempro and premphase should not be used during lactation. estrogen administration to nursing mothers has been shown to decrease the quanti

ארצות הברית - אנגלית - NLM (National Library of Medicine)

dispensing solutions, inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - estrogens, conjugated 0.3 mg - prempro or premphase therapy should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active deep vein thrombosis, pulmonary embolism or a history of these conditions - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions - known liver dysfunction or disease - known thrombophilic disorders (e.g., protein c, protein s, or antithrombin deficiency) - known or suspected pregnancy prempro and premphase should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. prempro and premphase should not be used during lactation. estrogen administration to nursing mothers has been shown to decrease the quanti

ארצות הברית - אנגלית - NLM (National Library of Medicine)

physicians total care, inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx), medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - estrogens, conjugated 0.3 mg - prempro or premphase therapy should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active deep vein thrombosis, pulmonary embolism or a history of these conditions - active arterial thromboembolic disease (for example, stroke and myocardial infarction), or a history of these conditions - known liver dysfunction or disease - known thrombophilic disorders (e.g., protein c, protein s, or antithrombin deficiency) - known or suspected pregnancy prempro and premphase should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. prempro and premphase should not be used during lactation. estrogen administration to nursing mothers has been shown to decrease the quanti